000130542 001__ 130542
000130542 005__ 20240228143442.0
000130542 0247_ $$2doi$$a10.1111/bpa.12326
000130542 0247_ $$2pmid$$apmid:26445087
000130542 0247_ $$2ISSN$$a1015-6305
000130542 0247_ $$2ISSN$$a1750-3639
000130542 0247_ $$2altmetric$$aaltmetric:4594851
000130542 037__ $$aDKFZ-2017-05621
000130542 041__ $$aeng
000130542 082__ $$a610
000130542 1001_ $$0P:(DE-He78)a23e88cc676489fe05be8c178ceaf58e$$aSelt, Florian$$b0$$eFirst author$$udkfz
000130542 245__ $$aPediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors.
000130542 260__ $$aOxford$$bWiley-Blackwell$$c2016
000130542 3367_ $$2DRIVER$$aarticle
000130542 3367_ $$2DataCite$$aOutput Types/Journal article
000130542 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524811115_6721
000130542 3367_ $$2BibTeX$$aARTICLE
000130542 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000130542 3367_ $$00$$2EndNote$$aJournal Article
000130542 520__ $$aThe 'pediatric targeted therapy' (PTT) program aims to identify the presence and activity of druggable targets and evaluate the clinical benefit of a personalized treatment approach in relapsed or progressive tumors on an individual basis. 10 markers (HDAC2, HR23B, p-AKT, p-ERK, p-S6, p-EGFR, PDGFR-alpha/beta, p53 and BRAFV600E) were analyzed by immunohistochemistry. Pediatric patients with tumors independent of the histological diagnosis, with relapse or progression after treatment according to standard protocols were included. N = 61/145 (42%) cases were eligible for analysis between 2009 and 2013, the most common entities being brain tumors. Immunohistochemical stainings were evaluated by the H-Score (0-300). In 93% of the cases potentially actionable targets were identified. The expressed or activated pathways were histone deacetylase (HDACs; 83.0% of cases positive), EGFR (87.2%), PDGFR (75.9%), p53 (50.0%), MAPK/ERK (43.3%) and PI3K/mTOR (36.1%). Follow-up revealed partial or full implementation of PTT results in treatment decision-making in 41% of the cases. Prolonged disease stabilization responses in single cases were noticed, however, response rates did not differ from cases treated with other modalities. Further studies evaluating the feasibility and clinical benefit of personalized diagnostic approaches using paraffin material are warranted.
000130542 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000130542 588__ $$aDataset connected to CrossRef, PubMed,
000130542 7001_ $$0P:(DE-He78)08356c94a2614430241904206d061f02$$aDeiß, Alica$$b1$$udkfz
000130542 7001_ $$0P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aKorshunov, Andrey$$b2$$udkfz
000130542 7001_ $$0P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aCapper, David$$b3$$udkfz
000130542 7001_ $$0P:(DE-He78)046fd145f1008f83f6236580727bbc0f$$aWitt, Hendrik$$b4$$udkfz
000130542 7001_ $$0P:(DE-He78)a6b5fcabf661bef95109dbee87dc5271$$avan Tilburg, Cornelis Martinus$$b5$$udkfz
000130542 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b6$$udkfz
000130542 7001_ $$0P:(DE-He78)4ad08e18c452a1684b5437a2f9a1052a$$aWitt, Ruth$$b7$$udkfz
000130542 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b8$$udkfz
000130542 7001_ $$0P:(DE-HGF)0$$aReuss, David$$b9
000130542 7001_ $$0P:(DE-He78)54ba44eb40f449fdb36646a0b9873eac$$aKölsche, Christian$$b10$$udkfz
000130542 7001_ $$0P:(DE-He78)3de637452ba900e2bdd359b8f41953bf$$aEcker, Jonas$$b11$$udkfz
000130542 7001_ $$0P:(DE-He78)908367a659dea9e28dac34592b3c46e5$$aOehme, Ina$$b12$$udkfz
000130542 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b13$$udkfz
000130542 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b14$$udkfz
000130542 7001_ $$aKulozik, Andreas E$$b15
000130542 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b16$$udkfz
000130542 7001_ $$0P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aWitt, Olaf$$b17$$udkfz
000130542 7001_ $$0P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aMilde, Till$$b18$$eLast author$$udkfz
000130542 773__ $$0PERI:(DE-600)2029927-8$$a10.1111/bpa.12326$$gVol. 26, no. 4, p. 506 - 516$$n4$$p506 - 516$$tBrain pathology$$v26$$x1015-6305$$y2016
000130542 909CO $$ooai:inrepo02.dkfz.de:130542$$pVDB
000130542 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a23e88cc676489fe05be8c178ceaf58e$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000130542 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)08356c94a2614430241904206d061f02$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000130542 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000130542 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000130542 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)046fd145f1008f83f6236580727bbc0f$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000130542 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a6b5fcabf661bef95109dbee87dc5271$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000130542 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000130542 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4ad08e18c452a1684b5437a2f9a1052a$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000130542 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000130542 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000130542 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)54ba44eb40f449fdb36646a0b9873eac$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000130542 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3de637452ba900e2bdd359b8f41953bf$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000130542 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)908367a659dea9e28dac34592b3c46e5$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000130542 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000130542 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000130542 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000130542 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000130542 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000130542 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000130542 9141_ $$y2016
000130542 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000130542 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000130542 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRAIN PATHOL : 2015
000130542 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000130542 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000130542 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000130542 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000130542 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000130542 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000130542 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000130542 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRAIN PATHOL : 2015
000130542 9201_ $$0I:(DE-He78)G340-20160331$$kG340$$lKKE Pädiatrische Onkologie$$x0
000130542 9201_ $$0I:(DE-He78)G380-20160331$$kG380$$lKKE Neuropathologie$$x1
000130542 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x2
000130542 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x3
000130542 9201_ $$0I:(DE-He78)G040-20160331$$kG040$$lKlinische Studienzentrale$$x4
000130542 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x5
000130542 980__ $$ajournal
000130542 980__ $$aVDB
000130542 980__ $$aI:(DE-He78)G340-20160331
000130542 980__ $$aI:(DE-He78)G380-20160331
000130542 980__ $$aI:(DE-He78)B062-20160331
000130542 980__ $$aI:(DE-He78)C060-20160331
000130542 980__ $$aI:(DE-He78)G040-20160331
000130542 980__ $$aI:(DE-He78)L101-20160331
000130542 980__ $$aUNRESTRICTED